tradingkey.logo

Novo Nordisk A/S

NVO
View Detailed Chart

66.400USD

+1.240+1.90%
Close 04/30, 16:00ETQuotes delayed by 15 min
223.50BMarket Cap
15.25P/E TTM

Novo Nordisk A/S

66.400

+1.240+1.90%
Intraday
1m
30m
1h
D
W
M
D

Today

+1.90%

5 Days

+8.32%

1 Month

-4.18%

6 Months

-41.36%

Year to Date

-22.81%

1 Year

-48.25%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 15 analysts
BUY
Current Rating
95.502
Target Price
46.57%
Rising Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

162
Total
6
Median
8
Average
Company name
Ratings
Analysts
Novo Nordisk A/S
NVO
15
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Amgen Inc
AMGN
33
Alnylam Pharmaceuticals Inc
ALNY
33
Gilead Sciences Inc
GILD
30
1
2
3
...
33

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Neutral
Sell(4)
Neutral(3)
Buy(4)
Indicators
Sell(1)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
1.761
Neutral
RSI(14)
47.447
Neutral
STOCH(KDJ)(9,3,3)
76.528
Buy
ATR(14)
2.964
Low Volatility
CCI(14)
92.072
Neutral
Williams %R
16.308
Overbought
TRIX(12,20)
-0.820
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(3)
Neutral(0)
Buy(3)
Indicators
Value
Direction
MA5
62.758
Buy
MA10
61.748
Buy
MA20
63.286
Buy
MA50
74.148
Sell
MA100
82.398
Sell
MA200
102.709
Sell

Company

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Company codeNVO
CompanyNovo Nordisk A/S
CEOMr. Lars Fruergaard Joergensen
Websitehttps://www.novonordisk.com/